NDAORALTABLET
Approved
Jan 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8
Mechanism of Action
drugs, a dihydropyridine calcium channel blocker (amlodipine) and an HMG-CoA reductase inhibitor (atorvastatin). The amlodipine component of amlodipine and atorvastatin tablets inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. The atorvastatin…
Clinical Trials (5)
Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients
Started Aug 2010
159 enrolled
HypertensionHypercholesterolemiaAngina Pectoris
Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Started Jun 2010
1,291 enrolled
HypertensionAngina PectorisHypercholesterolemia+1 more
Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors
Started Dec 2007
112 enrolled
Hypertension and Cardiovascular Risk Factors
Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors
Started Mar 2007
1,531 enrolled
HypertensionHypercholesterolemia
Caduet in an Untreated Subject Population
Started Jun 2006
220 enrolled
HypertensionDyslipidemia